<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762032</url>
  </required_header>
  <id_info>
    <org_study_id>DCS-71-14</org_study_id>
    <nct_id>NCT02762032</nct_id>
  </id_info>
  <brief_title>Natreon Healthy Skin Study - PrimaVie Supplement</brief_title>
  <official_title>The Ability of an Oral Supplement to Improve Skin Microperfusion, Hydration, Elasticity, and Barrier Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Natreon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will demonstrate the ability of the oral supplement, PrimaVieÂ® to improve skin
      microperfusion, hydration, elasticity and barrier function. 45 females will be enrolled in 1
      of 3 arms where they will receive either 125 mg PrimaVie, 250 mg PrimaVie or placebo
      (control) to take twice daily for 14 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be assessed based on they type of Fitzpatrick skin type they have, will be
      return for a total of 6 study visits over 14 weeks where the following research activities
      will take place through the course of the study: medical/dietary history, medications will be
      recorded, supplement randomization based on one of the three arms will occur at study visit
      1, and distribution of the study product will occur at all study visits, supplement
      tolerabiltity assessment, investigator and subject appearance assessment, photography of the
      face (left, right and front) will be taken, non-invasive assessments including
      Trans-epidermal Water Loss, hydration, elasticity, laser speckle perfusion, a skin biopsy of
      left inner upper arm (only at study visits 2 and 6), adverse event review, and supplement
      count/compliance review.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in non-invasive skin assessment of skin microperfusion</measure>
    <time_frame>14 weeks after oral supplementation</time_frame>
    <description>To see the improvement in noninvasive skin assessment of objective measurements such as skin microperfusion (laser speckle contrast imaging) (scale Pu)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in non-invasive skin assessment of hydration</measure>
    <time_frame>14 weeks after oral supplementation</time_frame>
    <description>To see the improvement in noninvasive skin assessment of objective measurements such as skin hydration using the DermaLab Combo Series (unit of micro-Siemens uS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in non-invasive skin assessment of elasticity</measure>
    <time_frame>14 weeks after oral supplementation</time_frame>
    <description>To see the improvement in noninvasive skin assessment of objective measurements such as skin elasticity using the DermaLab Combo Series (mega Pascal mPa and ms units)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in non-invasive skin assessment of barrier function</measure>
    <time_frame>14 weeks after oral supplementation</time_frame>
    <description>To see the improvement in noninvasive skin assessment of objective measurements such as barrier function using Trans-Epidermal Water Loss using the DermaLab Combo Series (g/m2/h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene Chip Analysis</measure>
    <time_frame>14 weeks</time_frame>
    <description>identify the up or down regulation of key youthful skin markers (gene expression) produced by the supplement over the placebo as identified by gene chip analysis after 14 weeks of oral supplementation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective visual assessment by photographs</measure>
    <time_frame>14 weeks</time_frame>
    <description>Identify subjectively by visual assessment, the effect of the PrimaVie supplement on skin appearance by the investigator/study physician at the end of 14 weeks of treatment from photographs taken at each time point.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PrimaVie Herbal Supplement 125</intervention_name>
    <description>125 mg to take BID for 14 weeks in Arm 1</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>PrimaVie</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PrimaVie Herbal Supplement 250</intervention_name>
    <description>250 mg to take BID for 14 weeks in Arm 2</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>PrimaVie</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplement to take BID for 14 weeks in Arm 3</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>control supplement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects willing to discontinue any dietary or nutritional supplements, other than a
             general multivitamin, starting two weeks before onset of study and also during the
             study.

          -  Subjects must be willing to maintain their present diet with no major changes
             throughout the study.

          -  Subjects must be willing to take the dietary supplements as required by the study
             protocol twice daily.

          -  Female subjects must be between the ages of 30 to 65 years of age

          -  Subjects must provide written informed consent and are willing to comply with all
             study procedures.

        Exclusion Criteria:

          -  Any dermatological disorder that may interfere with the accurate evaluation of the
             subject's skin.

          -  Subjects who are pregnant, breast feeding, or planning a pregnancy.

          -  Clinically significant unstable medical disorders.

          -  History of, diabetes, heart or kidney disease

          -  History of a psychological illness or condition that would interfere with their
             ability to understand and follow the requirements of the study.

          -  Any skin disease in the area of the upper inner arm where the biopsies will be
             obtained.

          -  Currently taking the following medications:

               -  Steroids

               -  Beta-blockers

               -  Immunosuppressant's

               -  Hydochlorothiazide,

               -  Statins

               -  Aspirin

               -  ACE Inhibitors

               -  Muscle relaxants

               -  Stimulants

          -  Prisoners

          -  Males
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gayle M Gordillo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth A Murphy, BS</last_name>
    <phone>9377283980</phone>
    <email>elizabeth.murphy@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gayle M Gordillo, M.D.</last_name>
    <phone>614-293-8566</phone>
    <email>gayle.gordillo@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OSU Hospital East</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Allison, RN</last_name>
      <phone>614-366-2783</phone>
      <email>Lauren.Allison@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Murphy, BS</last_name>
      <phone>614-685-3173</phone>
      <email>elizabeth.murphy@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Davis Heart and Lung Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sashwati Roy, Ph.D</last_name>
      <phone>614-247-7657</phone>
      <email>sashwati.roy@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martha Morehouse Medical Plaza 2050 Kenny Road</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy H Hoover, LPN</last_name>
      <phone>614-293-0390</phone>
      <email>Amy.Hoover@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gayle M Gordillo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Gayle Gordillo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Skin Biopsy</keyword>
  <keyword>PrimaVie</keyword>
  <keyword>Herbal Supplement</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

